|
Hot Stocks
| ShowHide Related Items >><< - 07:16 Today
- BiondVax names Amir Reichman as new CEO
- 01/12/21
- Vir Biotechnology, GlaxoSmithKline to evaluate VIR-7832 in COVID-19 patients
- 01/11/21
- Eligo Bioscience enters research, option agreement with GlaxoSmithKline
- 12/21/20
- Ligand, GSK in pact 'leveraging' Icagen's small molecule 'expertise'
- 07:09 Today
- Cerevel Therapeutics appoints Deval Patrick, Deborah Baron to board
- 01/20/21
- Pfizer, BioNTech: COVID-19 vaccine elicits antibodies neutralizing pseudovirus
- 01/14/21
- Pfizer says FDA approves supplemental NDA for Xalkori
- 01/14/21
- Oragenics issues letter to stockholders on Terra CoV-2
- 05:33 Today
- Addex Therapeutics receives IND approval to start study in epilepsy
- 01/19/21
- Royalty Pharma acquires royalty interest in Seltorexant from Minerva
- 01/19/21
- Minerva, Royalty Pharma announce sale of seltorexant royalty for up to $155M
- 01/15/21
- Halozyme says Janssen receives FDA approval of Darzalex Faspro
- 01/20/21 UBS
- GlaxoSmithKline price target raised to 1,450 GBp from 1,440 GBp at UBS
- 01/20/21
- Fly Intel: Top five analyst downgrades
- 01/20/21 Credit Suisse
- GlaxoSmithKline downgraded to Underperform from Neutral at Credit Suisse
- 01/20/21 Credit Suisse
- GlaxoSmithKline downgraded to Underperform from Neutral at Credit Suisse
- 01/14/21 Morgan Stanley
- 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
- 01/14/21 Oppenheimer
- Essa Pharma price target raised to $20 from $9 at Oppenheimer
- 01/05/21 Argus
- Viatris initiated with a Hold at Argus
- 12/31/20 Ladenburg
- UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
- 01/15/21 B. Riley Securities
- Arcturus Therapeutics downgraded to Neutral from Buy at B. Riley Securities
- 01/14/21 Morgan Stanley
- 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
- 01/14/21 Oppenheimer
- Essa Pharma price target raised to $20 from $9 at Oppenheimer
- 12/29/20 Piper Sandler
- Piper still believes in Arcturus vaccine after 'underwhelming' immunogenicity
- 10/28/20
- GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range
- 10/28/20
- GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago
- 10/08/20
- GlaxoSmithKline sees impact of foreign exchange on Q3 sales of about 5%
- 07/29/20
- GlaxoSmithKline reports Q2 adjusted EPS 19.2p, down 37% AER
- 01/12/21
- Pfizer sees FY21 EPS around $3.00-$3.10, consensus $3.07
- 10/27/20
- Pfizer sees FY20 Upjohn revenue $8B-$8.5B, adjusted EBITDA $3.8B-$4.2B
- 10/27/20
- Pfizer sees FY20 adjusted EPS for New Pfizer $2.28-$2.38, revenue $40.8B-$42.4B
- 10/27/20
- Pfizer narrows FY20 adjusted EPS view to $2.88-$2.93 from $2.85-$2.95
- 10/13/20
- Johnson & Johnson sees 'robutst, double-digit sales growth' in 2021
- 10/13/20
- Johnson & Johnson sees Q4 sales 'around' 2019 levels, consensus $21.52B
- 10/13/20
- Johnson & Johnson raises FY20 adj. EPS view to $7.95-$8.05 from $7.75-$7.95
- 10/13/20
- Johnson & Johnson reports Q3 adj. EPS $2.20, consensus $1.98
- 01/12/21
- GSK looks to double blockbusters in portfolio by 2026, Bloomberg says
- 12/31/20
- Drugmakers to hike U.S. prices on over 200 drugs, Reuters reports
- 12/23/20
- Judge rules against White House drug pricing rule, Reuters says
- 12/11/20
- GlaxoSmithKline offered $120 per share for Eidos Therapeutics, Bloomberg says
- 15:21 Today
- Pfizer slashes vaccine deliveries to some EU countries by 50%, Reuters reports
- 14:52 Today
- Pfizer and BioNTech agree to supply vaccine to WHO co-led effort, Reuters says
- 01/20/21
- Hong Kong set to approve COVID vaccine by Pfizer/BioNTech, SCMP says
- 01/20/21
- Japan inks deal with Pfizer for COVID vaccine for 72M people, Nikkei reports
- 01/13/21
- Johnson & Johnson's one-dose COVID-19 vaccine appears 'promising,' CNBC says
- 01/13/21
- J&J chief science officer sees possible vaccine approval by March, Reuters says
- 01/13/21
- J&J sees U.S. decision on COVID-19 vaccine candidate by March, Bloomberg says
- 01/13/21
- EU lawmaker says J&J likely to submit vaccine approval in Feb., Reuters reports
- 12/31/20
- Fly Intel: Wall Street's top stories for Thursday
- 12/26/20
- Week in review: How Trump's policies moved stocks
- 12/11/20
- Fly Intel: Wall Street's top stories for Friday
- 12/11/20
- Fly Intel: Wall Street's top stories at midday
- 01/12/21
- Fly Intel: Wall Street's top stories for Tuesday
- 01/12/21
- Fly Intel: Wall Street's top stories at midday
- 01/08/21
- Fly Intel: Wall Street's top stories for Friday
- 01/08/21
- Fly Intel: Wall Street's top stories at midday
- 01/14/21
- Fly Intel: Wall Street's top stories for Thursday
- 01/14/21
- Fly Intel: Wall Street's top stories at midday
- 01/13/21
- Fly Intel: Wall Street's top stories for Wednesday
- 12/29/20
- Street Fight: Citi sees opportunity in Arcturus as COVID data prompts downgrades
- 09/04/20
- GlaxoSmithKline call volume above normal and directionally bullish
- 08/03/20
- Unusually active option classes on open August 3rd
- 07/31/20
- Unusually active option classes on open July 31st
- 12/15/20
- Notable open interest changes for December 15th
- 12/14/20
- Unusually active option classes on open December 14th
- 12/11/20
- Unusually active option classes on open December 11th
- 12/11/20
- Notable open interest changes for December 11th
- 12/01/20
- Johnson & Johnson call volume above normal and directionally bullish
- 10/13/20
- Unusually active option classes on open October 13th
- 09/23/20
- Unusually active option classes on open September 23rd
- 08/24/20
- Unusually active option classes on open August 24th
|
|
On The Fly
| ShowHide Related Items >><< - 10:56 Today
- United expects international profits to turn more quickly than domestic
- 10:42 Today
- United says EBITDA margins should exceed 2019 levels by 2023
- 01/20/21
- United Airlines reports Q4 total passengers down 63.2% y/y
- 01/05/21
- CEO says XpresSpa adding more airport, airlines on-site COVID test locations
- 07:09 Today
- Travelers reports Q4 consolidated combined ratio of 86.7%
- 06:58 Today
- Travelers reports book value per share of $115.68, up 14% from year-end 2019
- 12/03/20
- Travelers acquires InsuraMatch from Plymouth Rock Group, terms not disclosed
- 10/20/20
- Travelers CEO says net written premiums in Q3 up nearly 3%
- $202.26 /
+0.915 (+0.45%) - 08:31 Today
- AbCellera-discovered antibody prevented COVID-19 in nursing homes, reduced risks
- 08:05 Today
- Eli Lilly: LY-CoV555 prevented Covid-19 at nursing homes in Blaze-2 trial
- 01/19/21
- Eli Lilly, Merus collaborate for novel T-cell re-directing bispecific antibodies
- 01/15/21
- Eli Lilly reports $30M limited partner investment in Unseen Capital Health Fund
- 08:31 Today
- AbCellera-discovered antibody prevented COVID-19 in nursing homes, reduced risks
- 01/19/21
- AbCellera granted U.S. patent covering Trianni Mouse technology
- 12/28/20
- AbCellera rises 1.5% after 5.3% stake disclosed by Peter Thiel in 13D filing
- 12/21/20
- AbCellera announces bamlanivimab to be evaluated in study for COVID-19 patients
- 12:52 Today
- Corteva confirms receipt of Starboard's intent to nominate directors
- 07:43 Today
- Starboard confirms nomination of eight candidates to Corteva's board
- 01/19/21
- Matrix Service subsidiary awarded construction of water facility by Corteva
- 01/04/21
- Corteva welcomes new Chief Technology Officer Sam Eathington
- 12/11/20
- CoreLogic expects final bids for company in early 2021
- 11/24/20
- CoreLogic board 'fully supportive' of 'robust' sale process
- 11/23/20
- Cannae, Senator ask CoreLogic to set board vote record date
- 11/17/20
- CoreLogic shareholders elect Senator, Cannae nominees to board
- $913.01 /
+12.01 (+1.33%) - 12/29/20
- Apartments.com Network acheives 1B website visits in 2020
- 12/18/20
- CoStar Group acquires Houses.com
- 12/17/20
- CoStar Group receives FTC clearance to close acquisition of Homesnap
- 11/30/20
- FTC sues to block CoStar Group's proposed acquisition of RentPath
- 10:00 Today
- Diebold rises 18.2%
- 09:47 Today
- Diebold rises 13.8%
- 09/30/20
- Co-op expands partnership with Diebold
- $78.02 /
+10.29 (+15.19%) - 12:00 Today
- TAL Education rises 13.8%
- 12/28/20
- TAL Education announces $3.3B private placement with Silver Lake-led investors
- 12/04/20
- Virgin Galactic unveils spacesuits developed in partnership with Under Armour
- 12/01/20
- Under Armour announces creation and launch of Curry Brand
- 10/30/20
- Under Armour says has line of sight to deliver slightly positive EPS in 2021
- 10/30/20
- Under Armour to sell MyFitnessPal platform to Francisco Partners in $345M deal
- 12/04/20
- Virgin Galactic unveils spacesuits developed in partnership with Under Armour
- 12/01/20
- Under Armour announces creation and launch of Curry Brand
- 10/30/20
- Under Armour says has line of sight to deliver slightly positive EPS in 2021
- 10/30/20
- Under Armour to sell MyFitnessPal platform to Francisco Partners in $345M deal
- 01/10/21
- Dyne Therapeutics announced new preclinical data from DM1 program
- 09/28/20
- Citadel Advisors takes 6.5% passive stake in Dyne Therapeutics
- 08:34 Today
- INmune Bio jumps 37% to $34.50 after disclosing XPro1595 data in AD
- 07:06 Today
- INmune Bio says XPro1595 found to decrease nueroinflammation biomarkers
- 01/13/21
- INmune Bio to host KOL webinar on Phase 1b trial of XPro1595
- 11/09/20
- INmune Bio doses first patient in Phase 2 trial of Quellor
- 01/14/21 Susquehanna
- United Airlines price target raised to $40 from $38 at Susquehanna
- 01/11/21 Cowen
- United Airlines upgraded to Outperform from Market Perform at Cowen
- 01/08/21
- Fly Intel: Top five analyst downgrades
- 01/08/21 BofA
- United Airlines downgraded to Underperform from Neutral at BofA
- 01/04/21 JPMorgan
- Travelers price target raised to $136 from $129 at JPMorgan
- 11/27/20 MKM Partners
- Travelers price target raised to $160 from $140 at MKM Partners
- 11/17/20 Barclays
- Travelers initiated with an Overweight at Barclays
- 10/29/20 BofA
- Chubb upgraded to Neutral at BofA with valuation gap to Travelers narrowed
- $202.26 /
+0.915 (+0.45%) - 01/20/21 Citi
- Citi opens 'positive Catalyst Watch' on Eli Lilly into Alzheimer's data
- 01/19/21 Roth Capital
- Merus price target raised to $32 from $19 at Roth Capital
- 01/19/21
- Fly Intel: Top five analyst upgrades
- 01/19/21 Mizuho
- Eli Lilly upgraded to Buy from Neutral at Mizuho
- 01/05/21
- Fly Intel: Top five analyst initiations
- 01/05/21 SVB Leerink
- SVB Leerink bullish on AbCellera, initiates with an Outperform
- 01/05/21 Berenberg
- AbCellera initiated with a Buy at Berenberg
- 01/05/21 Credit Suisse
- AbCellera initiated with an Outperform at Credit Suisse
- 05:12 Today Redburn
- Corteva downgraded to Neutral from Buy at Redburn
- 01/19/21 Deutsche Bank
- Corteva named 'Catalyst Call: Buy Idea' at Deutsche Bank
- 01/08/21 Deutsche Bank
- Corteva price target raised to $50 from $40 at Deutsche Bank
- 12/18/20 Susquehanna
- Corteva downgraded to Neutral from Positive at Susquehanna
- 01/06/21 Wolfe Research
- CoreLogic downgraded to Underperform from Peer Perform at Wolfe Research
- 12/01/20 Truist
- CoreLogic downgraded to Hold from Buy at Truist
- 12/01/20 Truist
- CoreLogic downgraded to Hold from Buy at Truist
- 10/28/20 Truist
- CoreLogic could be sold for 'meaningfully more' than $80 per share, says Truist
- $913.01 /
+12.01 (+1.33%) - 12/22/20 JMP Securities
- RealPage price target raised to $101 from $80 at JMP Securities
- 11/23/20 Wells Fargo
- CoStar Group price target raised to $990 from $915 at Wells Fargo
- 10/28/20 Truist
- CoreLogic could be sold for 'meaningfully more' than $80 per share, says Truist
- 10/28/20 Needham
- CoStar Group price target raised to $1,000 from $825 at Needham
- 06:02 Today JPMorgan
- JPMorgan upgrades 'deep value stock' Diebold to Overweight
- 04:47 Today JPMorgan
- Diebold upgraded to Overweight from Neutral at JPMorgan
- 10/27/20 JPMorgan
- Diebold assumed with a Neutral at JPMorgan
- 10/27/20 JPMorgan
- NCR Corp. upgraded to Overweight from Neutral at JPMorgan
- $78.02 /
+10.29 (+15.19%) - 12/30/20 Credit Suisse
- Credit Suisse cuts TAL target to $79 on margin pressure from online competition
- 12/29/20 CLSA
- TAL Education now has 'war chest' to fight competition, says CLSA
- 11/25/20 Morgan Stanley
- OneSmart downgraded to Equal Weight on margin pressure at Morgan Stanley
- 10/26/20 JPMorgan
- TAL Education downgraded to Neutral from Overweight at JPMorgan (Friday)
- 06:21 Today Deutsche Bank
- Under Armour upgraded to Buy from Hold at Deutsche Bank
- 06:06 Today Deutsche Bank
- Under Armour upgraded to Buy from Hold at Deutsche Bank
- 01/15/21 B. Riley Securities
- Under Armour price target raised to $15 from $13 at B. Riley Securities
- 01/07/21 JPMorgan
- Under Armour price target raised to $19 from $17 at JPMorgan
- 06:21 Today Deutsche Bank
- Under Armour upgraded to Buy from Hold at Deutsche Bank
- 01/15/21 B. Riley Securities
- Under Armour price target raised to $15 from $13 at B. Riley Securities
- 01/07/21 JPMorgan
- Under Armour price target raised to $19 from $17 at JPMorgan
- 01/04/21 Pivotal Research
- Under Armour upgraded to Buy from Hold at Pivotal Research
- 01/07/21 Piper Sandler
- Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
- 10/12/20 Jefferies
- Dyne Therapeutics initiated with a Buy at Jefferies
- 10/12/20 JPMorgan
- Dyne Therapeutics initiated with an Overweight at JPMorgan
- 10/12/20 Stifel
- Dyne Therapeutics initiated with a Buy at Stifel
- 09/01/20 BTIG
- INmune Bio initiated with a Buy at BTIG
- 07/14/20 Roth Capital
- INmune Bio price target raised to $26 from $13 at Roth Capital
- 03/12/20 H.C. Wainwright
- INmune Bio price target lowered to $8 from $11 at H.C. Wainwright
- 03/11/20 Roth Capital
- INmune makes progress in all programs, novel COVID-19 approach,says Roth Capital
- 01/20/21
- United Airlines ended 2020 with $19.7B in available liquidity
- 01/20/21
- United sees Q1 operating revenue down 65%-70%, consensus $4.06B
- 01/20/21
- United Airlines reports Q4 adjusted EPS ($7.00), consensus ($6.60)
- 01/20/21
- Notable companies reporting after market close
- 06:57 Today
- Travelers reports Q4 core EPS $4.91, consensus $3.18
- 10/20/20
- Travelers reports Q3 core EPS $3.12, consensus $3.00
- 07/23/20
- Travelers reports Q2 core EPS (20c), consensus (20c)
- 07/23/20
- Travelers reports Q2 core EPS (20c), consensus (20c)
- $202.26 /
+0.915 (+0.45%) - 12/15/20
- Eli Lilly sees FY21 EPS $7.75-$8.40, consensus $8.07
- 12/15/20
- Eli Lilly raises FY20 EPS view to $7.45-$7.65 from $7.20-$7.40, consensus $7.32
- 12/02/20
- Eli Lilly says updated purchase of LY-CoV555 to boost FY20 EPS view by 25c
- 10/27/20
- Eli Lilly backs FY20 adj. EPS view $7.20-$7.40, consensus $7.28
- 11/04/20
- Corteva backs FY20 operating EPS view $1.25-$1.45, consensus $1.38
- 11/04/20
- Corteva reports Q3 adjusted EPS (39c), consensus (42c)
- 11/04/20
- Notable companies reporting after market close
- 08/05/20
- Corteva sees FY20 operating EPS $1.25-$1.45, consensus $1.40
- 12/11/20
- CoreLogic raises FY21 adjusted EPS view to $4.40-$4.65 from $4.00-$4.20
- 12/11/20
- CoreLogic raises FY20 adjusted EPS view to $4.15-$4.25 from $3.65
- 10/22/20
- CoreLogic sees FY20 results at upper end of guidance range
- 10/22/20
- CoreLogic reports Q3 EPS $1.21, consensus $1.24
- $913.01 /
+12.01 (+1.33%) - 10/27/20
- CoStar Group sees FY20 EPS $9.39-$9.49, consensus $9.36
- 10/27/20
- CoStar Group sees Q4 EPS $2.34-$2.44, consensus $2.51
- 10/27/20
- CoStar Group reports Q3 EPS $2.26, consensus $2.07
- 07/28/20
- CoStar Group sees FY20 adjusted EPS $9.22-$9.42, consensus $9.11
- 10/28/20
- Diebold raises 2020 revenue view to $3.85B from $3.7B-$3.9B, consensus $3.83B
- 10/28/20
- Diebold reports Q3 non-GAAP EPS 28c, consensus 27c
- 07/30/20
- Diebold sees 2020 revenue $3.7B-$3.9B, consensus $3.79B
- 07/30/20
- Diebold reports Q2 non-GAAP EPS 38c, consensus 1c
- $78.02 /
+10.29 (+15.19%) - 05:21 Today
- TAL Education sees Q4 revenue $1.18B-$1.2B, consensus $1.17B
- 05:19 Today
- TAL Education reports Q3 EPS 2c, consensus 7c
- 10/22/20
- TAL Education sees Q3 revenue $1.06B-$1.09B, consensus $1.14B
- 10/22/20
- TAL Education reports Q2 EPS 8c, consensus 12c
- 10/30/20
- Under Armour sees FY20 adj. EPS (49c)-(47c), consensus (72c)
- 10/30/20
- Under Armour sees Q4 revenue down low-teen percentage rate, consensus $1.12B
- 10/30/20
- Under Armour reports Q3 adj. EPS 26c, consensus 3c
- 10/29/20
- Notable companies reporting before tomorrow's open
- 10/30/20
- Under Armour sees FY20 adj. EPS (49c)-(47c), consensus (72c)
- 10/30/20
- Under Armour sees Q4 revenue down low-teen percentage rate, consensus $1.12B
- 10/30/20
- Under Armour reports Q3 adj. EPS 26c, consensus 3c
- 10/29/20
- Notable companies reporting before tomorrow's open
- 11/05/20
- Dyne Therapeutics reports Q3 EPS ($2.01), consensus (87c)
- 11/05/20
- INmune Bio reports Q3 EPS (36c), consensus (17c)
|